Administrative Core

行政核心

• 批准号: 10328139
• 负责人: DAVID B. WEINER
• 金额: $ 27.52万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-22 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10328139
• 关键词: 2019-nCoV; Animals; Biochemistry; Bioinformatics Shared Resource; Biometry; Communication; Coronavirus; Data; Databases; Decision Making; Development; Doctor of Philosophy; Ensure; Event; Feedback; Financial Support; Funding; Future; Goals; Human; Human Resources; Immunity; Immunologist; Immunology; Indiana; Intellectual Property; Leadership; Link; Middle East Respiratory Syndrome Coronavirus; Molecular; Monitor; Nucleic Acid Vaccines; Nucleic Acids; Pennsylvania; Performance; Persons; Program Reviews; Progress Reports; Protein Engineering; Publications; Reagent; Reporting; Research; Research Project Grants; Resources; Running; SARS coronavirus; Sampling; Science; Shipping; Ships; Structural Biologist; Teleconferences; Telephone; The Wistar Institute; TimeLine; United States National Institutes of Health; Universities; Update; Videoconferencing; Virus; Work; Zoonoses; archive data; archived data; conflict resolution; experience; gene therapy; human coronavirus; meetings; member; nanoparticle delivery; next generation; novel coronavirus; novel vaccines; nucleic acid delivery; open data; programs; synthetic nucleic acid; transmission process; universal coronavirus vaccine; vaccine strategy; vaccinology; virology; zoonotic coronavirus

Project Summary The goal of this Program is to develop a next-generation, universal coronavirus synthetic nucleic acid vaccine employing advancements in nucleic acid delivery of nanoparticles that will provide broad protection against multiple seasonal and emerging CoV. There are seven CoV known to infect people, 4 human (HCoV-NL63, - 229E, -OC43, -HKU1) and 3 zoonotic that have crossed into humans in the past 20 years (SARS-CoV-1, SARS- CoV-2, and MERS-CoV). Zoonotic CoV are introduced by cross-transmission events from animals and the most concerning due to lack of immunity in people. Spread of future related viruses is of concern and new vaccine strategies are urgently needed that will provide broad protection in people against multiple coronaviruses. This program brings together the expertise of teams from The Wistar Institute (Drs. Weiner, Kulp, and Patel), The University of Pennsylvania (Dr. Allman), and Indiana University (Dr. Pallesen). Together, the team has significant experience in virology, immunology, protein engineering, and molecular and cellular biochemistry. The Program is organized into 2 Research Projects, overseen by the Administrative Core (AC). Dr. Ami Patel (The Wistar Institute) will serve as director for the AC. The goal of the Administrative core (AC), led by Dr. Patel as part of a three-member leadership team consisting of Dr. Kulp, Weiner and Patel, will provide overall governance and oversight to ensure the Program goals are met. These goals will be achieved through active program management including administrative and financial support, project monitoring and reporting, research compliance oversight, team communication, resource management, conflict resolution, and intellectual property management. In these functions, the AC will be responsible for overall program performance, personnel, sample distribution, and animal shipping coordination. The AC will arrange regular team calls for open data discussion and timeline review and organize yearly review meetings. The AC will arrange calls between the Program Direction, Project Leads and the NIH Program Office and provide yearly reports on progress for program feedback as well as facilitate publication of findings and scientific meeting attendance.

项目摘要 该计划的目标是开发下一代通用冠状病毒合成核酸疫苗 利用纳米颗粒的核酸递送的进步， 多种季节性和新冠病毒。已知有7种CoV感染人类，4种人类（HCoV-NL 63，-HCoV-NL 63）。 229 E、-OC 43、-HKU 1）和3种在过去20年中已交叉进入人类的人畜共患病（SARS-CoV-1、SARS-CoV-229 E、-OC 43、-HKU 1）。 CoV-2和MERS-CoV）。人畜共患冠状病毒是通过动物的交叉传播事件引入的， 因为人们缺乏免疫力。未来相关病毒的传播令人担忧，新疫苗 迫切需要制定战略，为人们提供广泛的保护，使其免受多种冠状病毒的侵害。 该计划汇集了来自Wistar研究所（Weiner，Kulp和Patel博士）， 宾夕法尼亚大学（Allman博士）和印第安纳州大学（Pallesen博士）。整个团队 在病毒学、免疫学、蛋白质工程和分子及细胞生物化学方面有丰富的经验。 该计划分为2个研究项目，由行政核心（AC）监督。Ami Patel博士 (The Wistar研究所）将担任AC的主任。 由Patel博士领导的行政核心（AC）的目标是作为三人领导团队的一部分， Kulp博士，韦纳和帕特尔，将提供全面的治理和监督，以确保该计划的目标是 met.这些目标将通过包括行政和财务在内的积极的计划管理来实现 支持、项目监控和报告、研究合规监督、团队沟通、资源 管理、冲突解决和知识产权管理。在这些功能中，AC将 负责整个项目的执行、人员、样品分发和动物运输协调。 AC将定期安排团队电话会议进行开放数据讨论和时间轴审查，并组织年度审查 会议. AC将安排项目指导、项目负责人和NIH项目办公室之间的电话联系 并提供年度进度报告，以供计划反馈，并促进调查结果的公布， 参加科学会议。